期刊
LANCET
卷 393, 期 10172, 页码 689-701出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(18)32596-0
关键词
-
资金
- Dutch National Epilepsy Fund [15-10]
- AC Thomson Foundation
- Netherlands Organisation for Health Research and Development
- Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, The Netherlands
- Federal Ministry of Education and Research
- Boll Foundation (Kerpen, Germany)
- National Health and Medical Research Council, National Institute of Neurological Disorders and Stroke
- Royal Melbourne Hospital Neuroscience Foundation
- UK Department of Health's Research Centres
- Marvin Weil Epilepsy Research Fund
- UK Epilepsy Society
- Nuts Ohra Fund
- Monash University
Epilepsy is one of the most common serious brain conditions, affecting over 70 million people worldwide. Its incidence has a bimodal distribution with the highest risk in infants and older age groups. Progress in genomic technology is exposing the complex genetic architecture of the common types of epilepsy, and is driving a paradigm shift. Epilepsy is a symptom complex with multiple risk factors and a strong genetic predisposition rather than a condition with a single expression and cause. These advances have resulted in the new classification of epileptic seizures and epilepsies. A detailed clinical history and a reliable eyewitness account of a seizure are the cornerstones of the diagnosis. Ancillary investigations can help to determine cause and prognosis. Advances in brain imaging are helping to identify the structural and functional causes and consequences of the epilepsies. Comorbidities are increasingly recognised as important aetiological and prognostic markers. Antiseizure medication might suppress seizures in up to two-thirds of all individuals but do not alter long-term prognosis. Epilepsy surgery is the most effective way to achieve long-term seizure freedom in selected individuals with drug-resistant focal epilepsy, but it is probably not used enough. With improved understanding of the gradual development of epilepsy, epigenetic determinants, and pharmacogenomics comes the hope for better, disease-modifying, or even curative, pharmacological and non-pharmacological treatment strategies. Other developments are clinical implementation of seizure detection devices and new neuromodulation techniques, including responsive neural stimulation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据